NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other EventsItem 8.01.Other Events.
On December 2, 2018, NewLink Genetics Corporation issued a press release titled "NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting."
A copy of the press release is attached hereto as Exhibits 99.1 and is incorporated herein by reference.
Section9 – Financial Statements and Exhibits
Item 9.01.FinancialStatements and Exhibits.
NEWLINK GENETICS CORP ExhibitEX-99.1 2 nlnk-20181203x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1NewLink GeneticsPresents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting –Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100%–Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities (RLTs) observedAmes,…To view the full exhibit click
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.